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Background and Aimes; Molecular mechanisms of pancreatic islet β-cell failure, a crucial 
pathological contributor to the development for diabetes mellitus have been extensively explored. 
Impairment of glucose-stimulated insulin secretion (GSIS) is an early feature of type2 diabetes, and 
influx of fatty acids into β-cells, β-cell lipotoxicity, has been thought to be involved in its 
pathogenesis. Sterol regulatory element-binding protein (SREBP)-1c is a transcription factor that 
controls hepatic lipogenesis and inhibited by polyunsatulated fatty acids such as eicosapentaenoate 
(EPA). In pancreatic β-cells, activation of SREBP-1c has been shown to be involved in impaired 
insulin secretion and glucose intolerance. In the current studies, the contribution of SREBP-1c to 
palmitate (PA) induced lipotoxicity and protective effect of EPA from lipotoxicty was investigated. 
Materials and Methods; Pancreatic islets isolated from C57BL/6 mice or SREBP-1-null mice were 
incubated without or with palmitate (PA) or PA-EPA. After incubation of islets, GSIS or 
potassium-(KSIS) stimulated insulin secretions and cellular insulin contents were measured. 
Expression profiles of mRNA and proteins were determined by real-time PCR and immunoblot 
analyses, respectively. Insulin secretion of pancreatic islet isolated from PA-rich diet fed mice and 
KK-Ay mice treated with or without EPA were also measured. 
Results: Incubation of isolated islets from C57BL/6 mice with PA caused inhibition of both GSIS 
and KSIS in dose-dependent manner, but addition of EPA restored both inhibitions. Concomitantly, 
PA activated, and EPA inhibited both mRNA and nuclear protein of SREBP-1c, accompanied by 
reciprocal changes of SREBP-1c-target genes such as IRS-2 and granuphilin. Suppression of 
IRS-2/Akt pathway could be a part of the downstream mechanism for the SREBP-1c-mediated 
insulin secretion defect because adenoviral constitutive activation of Akt (dominant positive form) 
compensated it. Uncoupling protein-2 also plays a crucial role in the PA inhibition of insulin 
secretion as confirmed by knockdown experiments, but that regulation is independent of SREBP-1c. 
The PA-EPA regulation of insulin secretion was similarly observed in islets from C57BL/6 mice 
pretreated with dietary manipulations. Furthermore, administration of EPA to diabetic KK-Ay mice 
ameliorated impairment of insulin secretion in their islets. 
Conclusions: EPA prevents PA-mediated insulin secretion defect through SREBP-1c inhibition, 
implicating a therapeutic potential for diabetes related to lipotoxicity. 
